loading...| Preferred Name |
Aclarubicin |
|
| Synonyms |
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1alpha,2beta,4beta))-(9CI) Antibiotic MA144-A1 Aclarubicin (1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-1-naphthacenecarboxylic acid methyl ester Aclacinomycin Aclacinomycin A ACLARUBICIN Aclacinomycin-A ACM-A MA144-A1 |
|
| Definitions |
An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C202 |
|
| CAS_Registry |
57576-44-0 |
|
| Chemical_Formula |
C42H53NO15 |
|
| code |
C202 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
FDA GDC HemOnc |
|
| DEFINITION |
An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin. |
|
| FDA_UNII_Code |
74KXF8I502 |
|
| FULL_SYN |
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1alpha,2beta,4beta))-(9CI) Antibiotic MA144-A1 Aclarubicin (1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-1-naphthacenecarboxylic acid methyl ester Aclacinomycin Aclacinomycin A ACLARUBICIN Aclacinomycin-A ACM-A MA144-A1 |
|
| Has_Salt_Form | ||
| Is_Value_For_GDC_Property | ||
| label |
Aclarubicin |
|
| Legacy Concept Name |
Aclarubicin |
|
| Maps_To |
Aclarubicin |
|
| NCI_Drug_Dictionary_ID |
39131 |
|
| NSC Number |
208734 240619 |
|
| PDQ_Closed_Trial_Search_ID |
39131 |
|
| PDQ_Open_Trial_Search_ID |
39131 |
|
| Preferred_Name |
Aclarubicin |
|
| prefixIRI |
Thesaurus:C202 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance Antibiotic |
|
| UMLS_CUI |
C0001143 |
|
| subClassOf |